

**Supplementary Table S6** Change in N-terminal pro-brain natriuretic peptide from baseline to Week 26

	Placebo				Selexipag				Treatment effect (95% CI)**
	n/N (%)	Median at baseline* (Q1, Q3)	Median at 26 weeks* (Q1, Q3)	Median change* (Q1, Q3)	n/N (%)	Median at baseline* (Q1, Q3)	Median at 26 weeks* (Q1, Q3)	Median change* (Q1, Q3)	
<b>PAH-CTD</b>	119/167 (71.3)	480.0 (142.0, 1674.0)	423.0 (132.0, 1784.0)	13.0 (-99.0, 404.0)	128/167 (76.6)	557.0 (161.0, 1637.5)	347.5 (109.0, 1447.5)	-55.5 (-282.5, 48.0)	-140.0 (-265, -51)
<b>PAH-SSc</b>	63/93 (67.7)	749.0 (270.0, 2043.0)	944.0 (232.0, 2716.0)	23.0 (-117.0, 582.0)	56/77 (72.7)	689.0 (203.5, 1733.0)	504.5 (173.0, 1724.0)	-25.5 (-249.5, 73.5)	-177.5 (-424, -31)
<b>PAH-SLE</b>	28/37 (75.7)	198.0 (91.5, 932.0)	161.0 (64.5, 682.5)	-36.5 (-93.5, 93.0)	37/45 (82.2)	335.0 (125.0, 1055.0)	207.0 (80.0, 583.0)	-63.0 (-380.0, -15.0)	-64.5 (-280, 20)
<b>PAH-MCTD/ CTD-other</b>	28/37 (75.7)	193.0 (85.5, 2142.5)	233.5 (48.0, 1694.0)	14.0 (-75.5, 440.5)	35/45 (77.8)	546.0 (165.0, 2059.0)	280.0 (125.0, 1621.0)	-38.0 (-305.0, 57.0)	-145.5 (-478, 14)

\*Values in ng per litre.

\*\*Point estimate for location shift as estimated by Hodges-Lehmann method.

Only patients with a non-missing value at both the baseline and at the visit are included.

CTD: connective tissue disease; MCTD: mixed connective tissue disease; N: number of patients in the population; n: number of patients with a value; PAH: pulmonary arterial hypertension; SLE: systemic lupus erythematosus; SSc: systemic sclerosis.